Plain language summary: how patients reported their experiences with avalglucosidase alfa and alglucosidase alfa in the COMET trial
This Plain Language Summary of Publication article (PLSP) from Future Rare Diseases compared two treatments for late-onset Pompe disease, a rare hereditary condition with severe symptoms affecting daily life. The research found that patients receiving avalglucosidase alfa reported more significant improvements than those receiving alglucosidase alfa across multiple areas: breathing ability, morning headaches, movement, overall physical and mental health, daily functions (including fatigue, pain, anxiety, depression, self-care, and daily activities), and selected activities.
Visit the site using this link to read the article.
This PLSP is based on an article called ‘Effect of avalglucosidase alfa on disease-specific and general patient-reported outcomes in treatment-naïve adults with late-onset Pompe disease compared with alglucosidase alfa: Meaningful change analyses from the Phase 3 COMET trial’ and was published in Molecular Genetics and Metabolism.
Visit Elsevier using the link to read the original article.